The content is available as a PDF (482.1 KB).
References
- 1.Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Hepatitis C. Intervention Therapy Group: Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556–567. doi: 10.1067/mcp.2000.110973. [DOI] [PubMed] [Google Scholar]
- 2.Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK. International Hepatitis Interventional Therapy Group: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958–965. doi: 10.1016/S0140-6736(01)06102-5. [DOI] [PubMed] [Google Scholar]
- 3.Sonnenblick M, Rosin AJ. Cardiotoxicity of interferon: A review of 44 cases. Chest. 1991;99:557–561. doi: 10.1378/chest.99.3.557. [DOI] [PubMed] [Google Scholar]
- 4.Conlon KC, Urba WJ, Smith JW, 2nd, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alphainterferon therapy. Cancer. 1990;65:2237–2242. doi: 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
- 5.Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant Interferon Alfa therapy for chronic hepatitis C. Chest. 1994;105:939–941. doi: 10.1378/chest.105.3.939. [DOI] [PubMed] [Google Scholar]
- 6.Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J. 1996;9:2691–2696. doi: 10.1183/09031936.96.09122691. [DOI] [PubMed] [Google Scholar]
- 7.Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK. Pegylated interferon and ribavirin induced interstitial pneumonitis with ARDS. Chest. 2003;124:406–410. doi: 10.1378/chest.124.1.406. [DOI] [PubMed] [Google Scholar]
- 8.Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest. 1994;106:612–613. doi: 10.1378/chest.106.2.612. [DOI] [PubMed] [Google Scholar]
- 9.Tahan V, Ozseker F, Guneylioglu D, Baran A, Ozaras R, Mert A, Ucisik AC, Cagatay T, Yilmazabayhan D, Senturk H. Sarcoidosis after use of interferon for chronic hepatitis C. Dig Dis Sci. 2003;48:169–173. doi: 10.1023/A:1021759120428. [DOI] [PubMed] [Google Scholar]
- 10.Bini EJ, Weinshel EH. Severe exacerbation of Asthma: A new side effect of interferon-α in patients with Asthma and chronic hepatitis C. Mayo Clin Proc. 1994;74:367–370. doi: 10.4065/74.4.367. [DOI] [PubMed] [Google Scholar]
- 11.Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The META VIR Cooperative Study Group. Hepatology. 1996;24:289–293. doi: 10.1002/hep.510240201. [DOI] [PubMed] [Google Scholar]
- 12.Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo controlled study. J Hepatol. 1996;25:591–598. doi: 10.1016/S0168-8278(96)80225-X. [DOI] [PubMed] [Google Scholar]
- 13.Abbas AK, Lichtman AH, Pober JS. Effector mechanism of immune responses Cellular and Molecular Immunology. Philadelphia: Saunders; 2000. pp. 235–335. [Google Scholar]
- 14.Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, Watanabe J, Miyamoto T, Ito K. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis. 1992;146:266–268. doi: 10.1164/ajrccm/146.1.266. [DOI] [PubMed] [Google Scholar]
- 15.Irving WL, Day S, Johnston ID. Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis. 1993;148:1683–1684. doi: 10.1164/ajrccm/148.6_Pt_1.1683. [DOI] [PubMed] [Google Scholar]